株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大腸癌:パイプライン製品の分析

Colorectal Cancer - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 232768
出版日 ページ情報 英文 1962 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.80円で換算しております。
Back to Top
大腸癌:パイプライン製品の分析 Colorectal Cancer - Pipeline Review, H2 2017
出版日: 2017年12月29日 ページ情報: 英文 1962 Pages
概要

大腸癌は、結腸または直腸から発生し始める癌で、その症状には、下痢や便秘、血便、激しい腹痛、満腹感や膨満感、原因不明の体重減、倦怠感、悪心、嘔吐などがあります。大腸癌を罹患する原因としては、喫煙、2型糖尿病、大腸癌を発症しやすい家系などが挙げられます。

当レポートでは、大腸癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

大腸癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

大腸癌:企業で開発中の治療薬

大腸癌:大学/機関で研究中の治療薬

大腸癌:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

大腸癌:企業で開発中の製品

大腸癌:大学/機関で研究中の製品

大腸癌の治療薬開発に従事している企業

大腸癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

大腸癌:休止中のプロジェクト

大腸癌:開発が中止された製品

大腸癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

目次
Product Code: GMDHC10020IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2017, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 26, 110, 143, 11, 175, 29 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 20, 9, 33 and 4 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Colorectal Cancer - Overview
  • Colorectal Cancer - Therapeutics Development
  • Colorectal Cancer - Therapeutics Assessment
  • Colorectal Cancer - Companies Involved in Therapeutics Development
  • Colorectal Cancer - Drug Profiles
  • Colorectal Cancer - Dormant Projects
  • Colorectal Cancer - Discontinued Products
  • Colorectal Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Colorectal Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
  • Colorectal Cancer - Pipeline by 3SBio Inc, H2 2017
  • Colorectal Cancer - Pipeline by 4SC AG, H2 2017
  • Colorectal Cancer - Pipeline by AB Science SA, H2 2017
  • Colorectal Cancer - Pipeline by AbbVie Inc, H2 2017
  • Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2017
  • Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2017
  • Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2017
  • Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2017
  • Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
  • Colorectal Cancer - Pipeline by AlfaSigma SpA, H2 2017
  • Colorectal Cancer - Pipeline by Allinky Biopharma, H2 2017
  • Colorectal Cancer - Pipeline by amcure GmbH, H2 2017
  • Colorectal Cancer - Pipeline by Amgen Inc, H2 2017
  • Colorectal Cancer - Pipeline by Amunix Operating Inc, H2 2017
  • Colorectal Cancer - Pipeline by Antibe Therapeutics Inc, H2 2017
  • Colorectal Cancer - Pipeline by APEIRON Biologics AG, H2 2017
  • Colorectal Cancer - Pipeline by Apexigen Inc, H2 2017
  • Colorectal Cancer - Pipeline by Aphios Corp, H2 2017
  • Colorectal Cancer - Pipeline by Aposense Ltd, H2 2017
  • Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals Inc, H2 2017
  • Colorectal Cancer - Pipeline by ARMO Biosciences Inc, H2 2017
  • Colorectal Cancer - Pipeline by ArQule Inc, H2 2017
  • Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2017
  • Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2017
  • Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
  • Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2017
  • Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
  • Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2017
  • Colorectal Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2017
  • Colorectal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
  • Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2017
  • Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
  • Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
  • Colorectal Cancer - Pipeline by Bayer AG, H2 2017
  • Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2017
  • Colorectal Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017
  • Colorectal Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
  • Colorectal Cancer - Pipeline by Biocon Ltd, H2 2017
  • Colorectal Cancer - Pipeline by Bionomics Ltd, H2 2017
  • Colorectal Cancer - Pipeline by Bionovis SA, H2 2017
  • Colorectal Cancer - Pipeline by Biotecnol Ltd, H2 2017
  • Colorectal Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2017
  • Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Colorectal Cancer - Pipeline by Boston Biomedical Inc, H2 2017
  • Colorectal Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Colorectal Cancer - Pipeline by Calithera Biosciences Inc, H2 2017
  • Colorectal Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017
  • Colorectal Cancer - Pipeline by Cantargia AB, H2 2017
  • Colorectal Cancer - Pipeline by Carna Biosciences Inc, H2 2017
  • Colorectal Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2017
  • Colorectal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
  • Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2017
  • Colorectal Cancer - Pipeline by Celgene Corp, H2 2017
  • Colorectal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
  • Colorectal Cancer - Pipeline by Cellectar Biosciences Inc, H2 2017
  • Colorectal Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2017
  • Colorectal Cancer - Pipeline by Celltrion Inc, H2 2017
  • Colorectal Cancer - Pipeline by Celyad SA, H2 2017
  • Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017
  • Colorectal Cancer - Pipeline by ChoDang Pharm Co Ltd, H2 2017
  • Colorectal Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Colorectal Cancer - Pipeline by Cleave Biosciences Inc, H2 2017
  • Colorectal Cancer - Pipeline by Cleveland BioLabs Inc, H2 2017
  • Colorectal Cancer - Pipeline by COARE Biotechnology Inc, H2 2017

List of Figures

  • Number of Products under Development for Colorectal Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top